Compounds > pyrroles
Page last updated: 2024-08-18

pyrroles and nvp-aew541

pyrroles has been researched along with nvp-aew541 in 80 studies

Research

Studies (80)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's25 (31.25)29.6817
2010's53 (66.25)24.3611
2020's2 (2.50)2.80

Authors

AuthorsStudies
Benini, S; Croci, S; García-Echeverría, C; Hofmann, F; Lollini, PL; Lukas, S; Manara, MC; Nicoletti, G; Perdichizzi, S; Picci, P; Scotlandi, K; Serra, M; Zambelli, D1
Kwan, W; Liu, S; Lubieniecka, JM; Nielsen, TO; Terry, J1
Blouin, MJ; Bruchim, I; Camirand, A; Gotlieb, WH; Gu, J; Pollak, MN; Shi, Y; Zhao, Y1
Baradari, V; Höpfner, M; Huether, A; Scherübl, H; Schuppan, D; Sutter, AP1
Baradari, V; Höpfner, M; Huether, A; Scherübl, H; Schöfl, C1
Robinson, SA; Rosenzweig, SA1
Frizelle, S; Jacobson, BA; Kratzke, RA; Maddaus, MA; Patel, MR; Whitson, BA; Yee, D1
Baradari, V; Hopfner, M; Huether, A; Scherubl, H; Sutter, AP1
Dominici, C; Mancini, C; Mancuso, M; McDowell, HP; Raschellà, G; Tanno, B; Vitali, R1
García-Echeverría, C; Hofmann, F; Landuzzi, L; Lollini, PL; Manara, MC; Nanni, C; Nanni, P; Nicoletti, G; Picci, P; Scotlandi, K; Zambelli, D1
Bortul, R; Evangelisti, C; Grafone, T; Martelli, AM; Martinelli, G; McCubrey, JA; Papa, V; Tabellini, G; Tazzari, PL1
Chesler, L; Gable, K; Goldenberg, DD; Goldfine, ID; Liu, D; Maddux, BA; Matthay, KK; Meyer, GE; Rosenthal, SM; Weiss, WA; Youngren, JF1
Brubaker, PL; Dubé, PE; Rowland, KJ1
Andraos, R; Cheong, R; Feinberg, AP; Iacobuzio-Donahue, CA; Kaneda, A; Ko, MS; Levchenko, A; Longo, DL; Ohlsson, R; Onyango, P; Pearson, MA; Sharov, AA; Timp, W; Wang, CJ; Wen, B1
Garayoa, M; García-Echeverría, C; Hofmann, F; Maiso, P; Montero, JC; Ocio, EM; Pandiella, A; San Miguel, JF; Zimmermann, J1
Gaumann, A; Geissler, EK; Lang, SA; Mori, A; Moser, C; Schachtschneider, P; Schlitt, HJ; Stoeltzing, O; Zimmermann, J1
Eisenberg, B; Flieder, D; Godwin, AK; Koumbi, D; Merkel, E; Pathak, H; Rink, L; Tarn, C; Testa, JR; von Mehren, M1
Adachi, Y; Arimura, Y; Carbone, DP; Ii, M; Imai, K; Imsumran, A; Lee, CT; Li, H; Li, R; Maehata, T; Piao, W; Shinomura, Y; Wang, Y; Yamamoto, H1
Borges, J; Esparís-Ogando, A; Ferreira, L; Ocaña, A; Pandiella, A; Rodríguez-Barrueco, R1
Foster, K; Wang, Y; Wright, C; Zhou, D1
Buettner, R; Czerwitzki, J; Endl, E; Friedrichs, N; Hartmann, W; Heukamp, LC; Holst, MI; Kawai, A; Koch, A; Küchler, J; Larsson, O; Metzger, D; Pietsch, T; Schulte, JH; Tanaka, S; Wardelmann, E; Wurst, P1
Cunningham, MP; Fan, Z; Green, M; Marks, C; Modjtahedi, H; Thomas, H1
Baumann, P; Franke, D; Hagemeier, H; Mandl-Weber, S; Schmidmaier, R1
Ishii, G; Jänne, PA; Minami, H; Mukohara, T; Nakatsura, T; Ogasawara, N; Park, JO; Saijo, N; Shimada, H; Shimomura, M; Wanikawa, R1
Adachi, Y; Arimura, Y; Carbone, DP; Imai, K; Imsumran, A; Lee, CT; Li, H; Li, R; Min, Y; Piao, W; Shinomura, Y; Wang, Y; Yamamoto, H1
Lorenz, J; Mössner, J; Wiedmann, M; Wolf, S1
Auernhammer, CJ; Brand, S; Göke, B; Lichtl, J; Rüden, Jv; Spöttl, G; Zitzmann, K1
Garcia-Echeverria, C; Hägerstrand, D; Hofmann, F; Lindh, MB; Nistér, M; Ostman, A; Peña, C1
Arias-Pulido, H; Brouwer-Visser, J; Goldberg, GL; Hebert, TM; Horwitz, SB; Huang, GS; Kim, CH; Lin, J; Prossnitz, ER; Qualls, CR; Ramirez, MJ; Smith, HO1
Gariboldi, MB; Monti, E; Ravizza, R1
Browne, BC; Clynes, M; Crown, J; Duffy, MJ; O'Donovan, N; Slamon, D; Venkatesan, N1
Jane, EP; Pollack, IF; Premkumar, DR1
de Jong, S; de Vries, EG; Kleibeuker, JH; Oenema, T; Pennarun, B; Stegehuis, JH2
Attias-Geva, Z; Bentov, I; Bruchim, I; Fishman, A; Werner, H1
Dai, W; Duan, C; Jiao, S; Korzh, V; Li, Y; Liu, Y; Lu, L; Zhou, J1
Abraham, J; Efstratiadis, A; Giles, FG; Keller, C; Kilcoyne, A; LeGallo, RD; Malempati, S; McCleish, AT; Nelon, LD; Nishijo, K; Nowak, BM; Prajapati, SI; Rubin, BP; Schaffer, BS; Taniguchi, E1
Brockhoff, M; Chène, P; Erdmann, D; Fontana, P; Hau, JC; Pover, AD; Zimmermann, C1
Bielen, A; Box, GM; de Haven Brandon, A; Eccles, SA; Gowan, S; Hargrave, D; Hofmann, F; Jeay, S; Jones, C; Jury, A; Martins, V; Perryman, L; Popov, S; Raynaud, FI; Valenti, M1
Haustermans, KM; Isebaert, SF; McBride, WH; Swinnen, JV1
Lorenz, J; Mössner, J; Thrum, S; Wiedmann, M1
Bellail, AC; Ding, L; Hao, C; Liu, Y; Lu, G; Olson, JJ; Sun, SY; Wang, G; Wei, F; Yuan, C1
Bielen, A; Bjerke, L; Box, G; Brandon, Ade H; Eccles, SA; Hofmann, F; Jamin, Y; Jeay, S; Jones, C; Jury, A; Martins, V; Perryman, L; Popov, S; Raynaud, FI; Robinson, SP; Romanet, V; Valenti, M1
Caviezel, C; Christofori, G; García-Echeverría, C; Hofmann, F; Pisarsky, L; Strittmatter, K; Zumsteg, A1
Alusi, G; Garcia, E; Giubellino, A; Grossman, AB; Korbonits, M; Nölting, S; Pacak, K1
Bao, XH; Fujiwara, T; Fukazawa, T; Hao, HF; Nagasaka, T; Naomoto, Y; Sakurama, K; Sun, DS; Takaoka, M; Wang, ZG; Yamatsuji, T1
Astolfi, A; Belfiore, A; Carè, A; Conte, A; Garofalo, C; Grilli, A; Manara, MC; Mancarella, C; Marino, MT; Picci, P; Scotlandi, K; Sigismund, S1
Ekyalongo, RC; Fujiwara, Y; Funakoshi, Y; Kataoka, Y; Kiyota, N; Minami, H; Mukohara, T; Tomioka, H1
Ballot, J; Browne, BC; Crown, J; Duffy, MJ; Eustace, AJ; Kennedy, J; Kennedy, S; Larkin, A; Madden, S; Mahgoub, T; McDermott, MS; O'Brien, NA; O'Donovan, N; Pedersen, K; Sclafani, F1
Dalgleish, A; Ioannou, N; Mackintosh, D; Modjtahedi, H; Seddon, AM1
Chang, YC; Cheng, AL; Hsu, C; Lee, BS; Lin, LI; Liou, JY; Ou, DL1
Cheng, AL; Hsu, C; Lee, BS; Liao, SC; Lin, LI; Liou, JY; Ou, DL1
Cohen, O; Cohen, ZR; Gorshtein, A; Hadani, M; Kammer, A; Rubinfeld, H; Shimon, I; Werner, H1
Bonzi, MC; Craparotta, I; Gariboldi, MB; Mancini, M; Monti, E; Pagin, M; Taiana, E1
Baxter, RC; Gill, AJ; Hugh, TJ; Julovi, SM; Pavlakis, N; Peters, L; Samra, JS; Smith, RC; Wong, MH; Xue, A1
Bruchim, I; Flescher, E; Reiss, A; Sarfstein, R; Werner, H1
Chen, Y; Chen, Z; Cho, H; Gray, NS; Griffin, JD; Liu, F; Liu, Q; Mitsiades, C; Nelson, E; Nonami, A; Sattler, M; Weisberg, E; Wong, KK; Zhang, J1
Bubendorf, L; Erne, P; Frachet, A; Frismantiene, A; Kyriakakis, E; Maslova, K; Pfaff, D; Philippova, M; Resink, TJ; Ruiz, C; Vlajnic, T1
Campbell, KH; Henderson, CJ; MacLeod, AK; McLaughlin, LA; McMahon, M; Wolf, CR1
Chang, MC; Chen, CA; Chen, TC; Chen, YL; Cheng, WF; Huang, CT1
Axelson, M; Berglund, M; Delforoush, M; Enblad, G; Feng, X; Georgii-Hemming, P; Larsson, O; Lennartsson, J; Lin, Y; Strömberg, T1
Akiyama, R; Anderson, JL; Denny, CT; Federman, N; Park, A; Tap, WD1
Cowan-Jacob, SW; Furet, P; Scheufler, C; Stauffer, F1
Boos, A; Chen, B; Fairhurst, RA; Furet, P; Guagnano, V; Jeay, S; Jiang, S; Lu, W; Marsilje, TH; McCarthy, C; Michellys, PY; Niklaus, M; Schnell, C; Stauffer, F; Stutz, S; Vaupel, A1
Lian, J; Ning, G; Qi, Y; Wang, W; Wang, X; Xu, L; Xu, Y; Zhu, Y1
Debelius, JW; Fowler, K; Grikscheit, TC; Holoyda, KA; Hou, X; Isani, M; Khuu, T; Knight, R; Lien, CL; Moats, RA; Pollack, HA; Salisbury, T; Schall, KA; Schlieve, C1
Li, W; Lin, Y; Liu, R; Ma, J; Shao, N; Shi, Y; Wang, S; Wu, W1
Bareja, A; Dzau, VJ; Hodgkinson, CP; Payne, AJ; Pratt, RE1
Bergh, A; Bergström, SH; Bovinder-Ylitalo, E; Lerner, UH; Nordstrand, A; Thysell, E; Widmark, A; Wikström, P1
Browne, BC; Canonici, A; Crown, J; Ivers, L; Madden, SF; McDermott, MSJ; O'Brien, NA; O'Donovan, N1
Ashrafi, GH; Modjtahedi, H; Seddon, AM; Stanley, A1
Fujishiro, M; Hayakawa, K; Hirai, T; Ikeda, K; Miyashita, T; Morimoto, S; Sekigawa, I; Takamori, K; Takasaki, Y; Tamura, N; Tsushima, H; Yamaji, K; Yoshida, Y1
Austin, D; Chau, B; Foos, K; Hamilton, N; Márquez-Garbán, D; Pietras, R; Sanchez, R; Vadgama, J; Wu, Y1
Bhalla, AD; Bolshakov, S; Ingram, DR; Kivlin, CM; Landers, SM; Lazar, AJ; Ma, X; May, CD; Sannaa, GAA; Torres, KE; Wang, WL; Watson, KL1
Engelke, LH; Gohr, K; Hamacher, A; Kassack, MU1
Alonso, V; Asensio, E; Camps, J; Castells, A; Codony-Servat, J; Cuatrecasas, M; Escudero, P; Feliu, J; Fernández-Martos, C; Gaba, L; Gallego, J; García-Albéniz, X; Horndler, C; Jares, P; Marín-Aguilera, M; Martín-Richard, M; Martínez-Balibrea, E; Martínez-Cardús, A; Maurel, J; Méndez, JC; Méndez, M; Montironi, C; Prat, A; Reig, O; Rojo, F; Rosell, R; Rubini, M; Salud, A; Victoria, I1
Deng, S; Jing, X; Qin, Q; She, Q; Wu, L; Yan, Y1
Chang, XF; Ding, X; Han, W; Qin, H; Wang, HM; Wang, J; Wang, X; Yang, W; Zhang, JZ; Zhu, ZY1
Cao, J; Chen, Y; Cheng, L; Hu, X; Hua, Q; Liu, S; Lu, D; Tan, F; Tian, Y; Wu, M; Yu, H1
Bahtiar, A; Fujio, Y; Kametani, Y; Kobayashi, A; Maeda, M; Matsumoto, K; Miyake, Y; Mori, S; Obana, M; Tanaka, S; Tomimatsu, M; Wahyuni, T; Yamamoto, A1

Other Studies

80 other study(ies) available for pyrroles and nvp-aew541

ArticleYear
Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors.
    Cancer research, 2005, May-01, Volume: 65, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bone Neoplasms; Cell Cycle; Cell Growth Processes; Cell Line, Tumor; Drug Screening Assays, Antitumor; Humans; Osteosarcoma; Pyrimidines; Pyrroles; Receptor, IGF Type 1; Rhabdomyosarcoma; Sarcoma; Sarcoma, Ewing; Signal Transduction; Vincristine

2005
Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin prevents synovial sarcoma proliferation via apoptosis in in vitro models.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Aug-01, Volume: 11, Issue:15

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Benzamides; Benzoquinones; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; ErbB Receptors; Flow Cytometry; Gefitinib; HSP90 Heat-Shock Proteins; Humans; Imatinib Mesylate; Immunoblotting; Immunohistochemistry; In Situ Hybridization, Fluorescence; In Vitro Techniques; Inhibitory Concentration 50; Lactams, Macrocyclic; Piperazines; Prognosis; Pyrimidines; Pyrroles; Quinazolines; Rifabutin; Sarcoma, Synovial; Trastuzumab

2005
Insulin-like growth factor receptor I targeting in epithelial ovarian cancer.
    Gynecologic oncology, 2006, Volume: 100, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Growth Processes; Cell Line, Tumor; Cisplatin; Dose-Response Relationship, Drug; Drug Synergism; Epithelial Cells; Female; Humans; Insulin-Like Growth Factor I; Insulin-Like Growth Factor II; Ovarian Neoplasms; Phosphorylation; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; Receptor, IGF Type 1

2006
Blockade of IGF-1 receptor tyrosine kinase has antineoplastic effects in hepatocellular carcinoma cells.
    Biochemical pharmacology, 2006, May-14, Volume: 71, Issue:10

    Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Cycle; Cell Line, Tumor; Cell Survival; DNA Fragmentation; Dose-Response Relationship, Drug; Drug Combinations; Enzyme Inhibitors; Hepatocytes; Humans; Liver Neoplasms; Pyrimidines; Pyrroles; Receptor, IGF Type 1; RNA, Messenger

2006
The insulin-like growth factor receptor 1 is a promising target for novel treatment approaches in neuroendocrine gastrointestinal tumours.
    Endocrine-related cancer, 2006, Volume: 13, Issue:1

    Topics: Antibiotics, Antineoplastic; Apoptosis; Caspase 3; Caspases; Cell Cycle; Doxorubicin; Drug Combinations; Fatty Acids, Monounsaturated; Fluvastatin; Gastrointestinal Neoplasms; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; L-Lactate Dehydrogenase; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Neuroendocrine Tumors; Pyrimidines; Pyrroles; Receptor, IGF Type 1; Signal Transduction; Tumor Cells, Cultured

2006
Paradoxical effects of the phage display-derived peptide antagonist IGF-F1-1 on insulin-like growth factor-1 receptor signaling.
    Biochemical pharmacology, 2006, Jun-28, Volume: 72, Issue:1

    Topics: Androstadienes; Cell Cycle; Cell Line, Tumor; DNA Replication; Humans; Insulin-Like Growth Factor Binding Protein 2; Insulin-Like Growth Factor Binding Protein 3; Insulin-Like Growth Factor I; Peptide Library; Peptides, Cyclic; Phosphorylation; Protein Binding; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; Receptor, IGF Type 1; Signal Transduction; Wortmannin

2006
Effects of insulin-like growth factor-1 receptor inhibition in mesothelioma. Thoracic Surgery Directors Association Resident Research Award.
    The Annals of thoracic surgery, 2006, Volume: 82, Issue:3

    Topics: Antineoplastic Agents; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; MAP Kinase Signaling System; Mesothelioma; Mitogen-Activated Protein Kinases; Neoplasm Proteins; Phosphorylation; Pleural Neoplasms; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; Receptor, IGF Type 1; Tumor Stem Cell Assay

2006
Tyrosine kinase of insulin-like growth factor receptor as target for novel treatment and prevention strategies of colorectal cancer.
    World journal of gastroenterology, 2006, Sep-21, Volume: 12, Issue:35

    Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle; Cell Line, Tumor; Cetuximab; Colorectal Neoplasms; Cytotoxins; Dose-Response Relationship, Drug; Fatty Acids, Monounsaturated; Fluvastatin; Gene Expression Regulation, Neoplastic; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; L-Lactate Dehydrogenase; Pyrimidines; Pyrroles; Receptor Protein-Tyrosine Kinases; Receptor, IGF Type 1

2006
Down-regulation of insulin-like growth factor I receptor activity by NVP-AEW541 has an antitumor effect on neuroblastoma cells in vitro and in vivo.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2006, Nov-15, Volume: 12, Issue:22

    Topics: Adrenal Gland Neoplasms; Animals; Antineoplastic Agents; Brain Neoplasms; Cell Proliferation; Down-Regulation; Humans; Kidney Neoplasms; Male; Mice; Mice, Nude; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Neoplasm Invasiveness; Neuroblastoma; Phosphorylation; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; Receptor, IGF Type 1; Transplantation, Heterologous; Tumor Burden; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2006
Preclinical in vivo study of new insulin-like growth factor-I receptor--specific inhibitor in Ewing's sarcoma.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2007, Feb-15, Volume: 13, Issue:4

    Topics: Animals; Female; Humans; Mice; Mice, Nude; Neoplasm Metastasis; Pyrimidines; Pyrroles; Receptor, IGF Type 1; Sarcoma, Ewing; Xenograft Model Antitumor Assays

2007
The insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 induces apoptosis in acute myeloid leukemia cells exhibiting autocrine insulin-like growth factor-I secretion.
    Leukemia, 2007, Volume: 21, Issue:5

    Topics: Apoptosis; Cyclin-Dependent Kinase Inhibitor p27; Cytarabine; Down-Regulation; Etoposide; HL-60 Cells; Humans; Insulin-Like Growth Factor I; Intracellular Signaling Peptides and Proteins; Leukemia, Myeloid, Acute; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Pyrimidines; Pyrroles; Receptor, IGF Type 1

2007
Nordihydroguaiaretic acid inhibits insulin-like growth factor signaling, growth, and survival in human neuroblastoma cells.
    Journal of cellular biochemistry, 2007, Dec-15, Volume: 102, Issue:6

    Topics: Animals; Apoptosis; Caspase 3; Cell Culture Techniques; Cell Movement; Cell Proliferation; Cell Survival; Cells, Cultured; Dose-Response Relationship, Drug; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Humans; Insulin-Like Growth Factor I; Masoprocol; Mice; Mice, Nude; Neuroblastoma; Phosphorylation; Propidium; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; Receptor, IGF Type 1; Signal Transduction; Xenograft Model Antitumor Assays

2007
Glucagon-like peptide-2 activates beta-catenin signaling in the mouse intestinal crypt: role of insulin-like growth factor-I.
    Endocrinology, 2008, Volume: 149, Issue:1

    Topics: Animals; beta Catenin; Fasting; Female; Glucagon-Like Peptide 2; High Mobility Group Proteins; Insulin-Like Growth Factor I; Intestinal Mucosa; Ki-67 Antigen; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Microvilli; Models, Biological; Oncogene Protein v-akt; Pyrimidines; Pyrroles; Receptor, IGF Type 1; Signal Transduction; SOX9 Transcription Factor; Transcription Factors

2008
Enhanced sensitivity to IGF-II signaling links loss of imprinting of IGF2 to increased cell proliferation and tumor risk.
    Proceedings of the National Academy of Sciences of the United States of America, 2007, Dec-26, Volume: 104, Issue:52

    Topics: Animals; Anticarcinogenic Agents; Azoxymethane; Cell Proliferation; DNA Methylation; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Genomic Imprinting; Insulin-Like Growth Factor II; Mice; Mice, Inbred C57BL; Neoplasms; Oligonucleotide Array Sequence Analysis; Pyrimidines; Pyrroles; Signal Transduction

2007
The insulin-like growth factor-I receptor inhibitor NVP-AEW541 provokes cell cycle arrest and apoptosis in multiple myeloma cells.
    British journal of haematology, 2008, Volume: 141, Issue:4

    Topics: Animals; Antineoplastic Agents; Apoptosis; Caspases; Cell Cycle; Cell Proliferation; Cytokines; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Insulin-Like Growth Factor I; Mice; Mice, Nude; Multiple Myeloma; Neoplasm Transplantation; Phosphorylation; Pyrimidines; Pyrroles; Receptor, IGF Type 1; Transplantation, Heterologous; Tumor Cells, Cultured

2008
Inhibition of insulin-like growth factor-I receptor (IGF-IR) using NVP-AEW541, a small molecule kinase inhibitor, reduces orthotopic pancreatic cancer growth and angiogenesis.
    European journal of cancer (Oxford, England : 1990), 2008, Volume: 44, Issue:11

    Topics: Angiogenesis Inhibitors; Animals; Cell Communication; Cell Movement; Cell Proliferation; Humans; Immunohistochemistry; Mice; Mice, Inbred BALB C; Neovascularization, Pathologic; Pancreatic Neoplasms; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Receptor, IGF Type 1

2008
Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors.
    Proceedings of the National Academy of Sciences of the United States of America, 2008, Jun-17, Volume: 105, Issue:24

    Topics: Antineoplastic Agents; Apoptosis; Benzamides; Cell Line, Tumor; Cell Proliferation; DNA Mutational Analysis; Gastrointestinal Stromal Tumors; Gene Amplification; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Imatinib Mesylate; Mitogen-Activated Protein Kinase Kinases; Mutation; Piperazines; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Receptor, IGF Type 1; Receptor, Platelet-Derived Growth Factor alpha; RNA, Small Interfering; Signal Transduction

2008
Insulin-like growth factor-I receptor blockade by a specific tyrosine kinase inhibitor for human gastrointestinal carcinomas.
    Molecular cancer therapeutics, 2008, Volume: 7, Issue:6

    Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Drug Synergism; Gastrointestinal Neoplasms; Humans; Insulin; Mice; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Receptor, IGF Type 1; Signal Transduction; Xenograft Model Antitumor Assays

2008
Synergic antitumoral effect of an IGF-IR inhibitor and trastuzumab on HER2-overexpressing breast cancer cells.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2008, Volume: 19, Issue:11

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Drug Synergism; Humans; Pyrimidines; Pyrroles; Receptor, ErbB-2; Receptor, IGF Type 1; Trastuzumab

2008
Dependence on PI3K/Akt signaling for malignant rhabdoid tumor cell survival.
    Cancer chemotherapy and pharmacology, 2009, Volume: 63, Issue:5

    Topics: Blotting, Western; Cell Proliferation; Cell Survival; HeLa Cells; Humans; Immunoprecipitation; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; ras Proteins; Receptor, IGF Type 1; Rhabdoid Tumor; Signal Transduction; Tumor Cells, Cultured

2009
Insulin-like growth factor-1 receptor acts as a growth regulator in synovial sarcoma.
    The Journal of pathology, 2008, Volume: 216, Issue:4

    Topics: Adult; Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Line, Tumor; Cell Movement; Cell Proliferation; Female; Fluorescent Antibody Technique; Humans; Insulin-Like Growth Factor II; Male; MAP Kinase Signaling System; Middle Aged; Phosphatidylinositol 3-Kinases; Phosphorylation; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; Receptor, IGF Type 1; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sarcoma, Synovial; Signal Transduction

2008
Co-targeting the EGFR and IGF-IR with anti-EGFR monoclonal antibody ICR62 and the IGF-IR tyrosine kinase inhibitor NVP-AEW541 in colorectal cancer cells.
    International journal of oncology, 2008, Volume: 33, Issue:5

    Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Cell Proliferation; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Epidermal Growth Factor; ErbB Receptors; HCT116 Cells; Humans; Insulin-Like Growth Factor I; Insulin-Like Growth Factor II; MAP Kinase Kinase Kinases; Mitogen-Activated Protein Kinases; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; Receptor, IGF Type 1

2008
Myeloma cell growth inhibition is augmented by synchronous inhibition of the insulin-like growth factor-1 receptor by NVP-AEW541 and inhibition of mammalian target of rapamycin by Rad001.
    Anti-cancer drugs, 2009, Volume: 20, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Delivery Systems; Drug Synergism; Everolimus; Humans; Multiple Myeloma; Phosphorylation; Protein Kinases; Pyrimidines; Pyrroles; Receptor, IGF Type 1; Sirolimus; Time Factors; TOR Serine-Threonine Kinases

2009
Sensitivity of breast cancer cell lines to the novel insulin-like growth factor-1 receptor (IGF-1R) inhibitor NVP-AEW541 is dependent on the level of IRS-1 expression.
    Cancer letters, 2009, Sep-08, Volume: 282, Issue:1

    Topics: Antineoplastic Agents; Blotting, Western; Breast Neoplasms; Cell Division; Cell Line, Tumor; Enzyme Inhibitors; Humans; Insulin Receptor Substrate Proteins; Phosphorylation; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Receptor Protein-Tyrosine Kinases; Receptor, IGF Type 1

2009
Insulin-like growth factor-I receptor blockade reduces the invasiveness of gastrointestinal cancers via blocking production of matrilysin.
    Carcinogenesis, 2009, Volume: 30, Issue:8

    Topics: Adenocarcinoma; Animals; Blotting, Western; Female; Fluorescent Antibody Technique; Gastrointestinal Neoplasms; Genes, Dominant; Humans; Immunoenzyme Techniques; Immunoprecipitation; Infusions, Subcutaneous; Matrix Metalloproteinase 7; Matrix Metalloproteinase Inhibitors; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Pyrimidines; Pyrroles; Receptor, IGF Type 1; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Somatomedins; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2009
Treatment of biliary tract cancer with NVP-AEW541: mechanisms of action and resistance.
    World journal of gastroenterology, 2010, Jan-14, Volume: 16, Issue:2

    Topics: Antineoplastic Agents; Biliary Tract Neoplasms; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Drug Synergism; Drug Therapy, Combination; Fluorouracil; Gallbladder Neoplasms; Gemcitabine; Humans; Proto-Oncogene Proteins c-akt; Pteridines; Pyrimidines; Pyrroles; Receptor, IGF Type 1

2010
Compensatory activation of Akt in response to mTOR and Raf inhibitors - a rationale for dual-targeted therapy approaches in neuroendocrine tumor disease.
    Cancer letters, 2010, Sep-01, Volume: 295, Issue:1

    Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Everolimus; Extracellular Signal-Regulated MAP Kinases; Feedback, Physiological; G1 Phase; Humans; Imidazoles; Intracellular Signaling Peptides and Proteins; MAP Kinase Signaling System; Neuroendocrine Tumors; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; Quinolines; raf Kinases; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A

2010
PI3K/PTEN/Akt pathway status affects the sensitivity of high-grade glioma cell cultures to the insulin-like growth factor-1 receptor inhibitor NVP-AEW541.
    Neuro-oncology, 2010, Volume: 12, Issue:9

    Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Glioma; Humans; Immunoblotting; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Pyrimidines; Pyrroles; Receptor, IGF Type 1; Reverse Transcriptase Polymerase Chain Reaction; RNA, Small Interfering; Signal Transduction

2010
Insulin-like growth factor 2 expression modulates Taxol resistance and is a candidate biomarker for reduced disease-free survival in ovarian cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2010, Jun-01, Volume: 16, Issue:11

    Topics: Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Cell Line, Tumor; Cell Proliferation; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gene Knockdown Techniques; Humans; Insulin-Like Growth Factor II; Ovarian Neoplasms; Paclitaxel; Phosphorylation; Prognosis; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; Receptor, IGF Type 1; RNA, Small Interfering; Signal Transduction

2010
The IGFR1 inhibitor NVP-AEW541 disrupts a pro-survival and pro-angiogenic IGF-STAT3-HIF1 pathway in human glioblastoma cells.
    Biochemical pharmacology, 2010, Aug-15, Volume: 80, Issue:4

    Topics: Angiogenesis Inhibitors; Cell Line, Tumor; Cell Survival; Drug Synergism; Glioblastoma; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Insulin-Like Growth Factor I; Pyrimidines; Pyrroles; Receptor, IGF Type 1; STAT3 Transcription Factor

2010
Inhibition of IGF1R activity enhances response to trastuzumab in HER-2-positive breast cancer cells.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2011, Volume: 22, Issue:1

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Growth Processes; Cell Line, Tumor; Combined Modality Therapy; Drug Resistance, Neoplasm; Drug Synergism; Female; Humans; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Receptor, ErbB-2; Receptor, IGF Type 1; RNA, Small Interfering; Transfection; Trastuzumab

2011
Co-administration of NVP-AEW541 and dasatinib induces mitochondrial-mediated apoptosis through Bax activation in malignant human glioma cell lines.
    International journal of oncology, 2010, Volume: 37, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2-Associated X Protein; Cell Cycle; Cell Cycle Proteins; Cell Growth Processes; Cell Line, Tumor; Dasatinib; Drug Synergism; Fluorescent Antibody Technique; Glioblastoma; Humans; Mitochondria; Phosphorylation; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Signal Transduction; Thiazoles; Transfection

2010
Inhibition of IGF-1R-dependent PI3K activation sensitizes colon cancer cells specifically to DR5-mediated apoptosis but not to rhTRAIL.
    Analytical cellular pathology (Amsterdam), 2010, Volume: 33, Issue:5

    Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Line, Tumor; Cell Separation; Colonic Neoplasms; Enzyme Activation; Flow Cytometry; Humans; Immunoprecipitation; Microscopy, Fluorescence; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Receptor, IGF Type 1; Receptors, TNF-Related Apoptosis-Inducing Ligand; Recombinant Proteins; Signal Transduction; TNF-Related Apoptosis-Inducing Ligand

2010
Insulin-like growth factor-I receptor inhibition by specific tyrosine kinase inhibitor NVP-AEW541 in endometrioid and serous papillary endometrial cancer cell lines.
    Gynecologic oncology, 2011, May-01, Volume: 121, Issue:2

    Topics: Apoptosis; Carcinoma, Endometrioid; Carcinoma, Papillary; Cell Cycle; Cell Growth Processes; Cell Line, Tumor; Cystadenocarcinoma, Serous; Endometrial Neoplasms; Female; Humans; Molecular Targeted Therapy; Phosphorylation; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Receptor, IGF Type 1; Receptor, Insulin; Signal Transduction

2011
The conserved clusterin gene is expressed in the developing choroid plexus under the regulation of notch but not IGF signaling in zebrafish.
    Endocrinology, 2011, Volume: 152, Issue:5

    Topics: Amino Acid Sequence; Animals; Cell Line, Tumor; Choroid Plexus; Clusterin; Female; Gene Expression Regulation, Developmental; Gene Knockout Techniques; Green Fluorescent Proteins; HEK293 Cells; Humans; In Situ Hybridization; Insulin-Like Growth Factor I; Male; Microscopy, Fluorescence; Molecular Sequence Data; Phylogeny; Pyrimidines; Pyrroles; Receptor, IGF Type 1; Receptors, Notch; Reverse Transcriptase Polymerase Chain Reaction; Sequence Homology, Amino Acid; Signal Transduction; Zebrafish; Zebrafish Proteins

2011
Evasion mechanisms to Igf1r inhibition in rhabdomyosarcoma.
    Molecular cancer therapeutics, 2011, Volume: 10, Issue:4

    Topics: Animals; Apoptosis; Blotting, Western; Cell Cycle; Cell Proliferation; Child; Chorioallantoic Membrane; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Embryo, Mammalian; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Mice; Phosphorylation; Pyrimidines; Pyrroles; Quail; Quinazolines; Receptor, ErbB-2; Receptor, IGF Type 1; Reverse Transcriptase Polymerase Chain Reaction; Rhabdomyosarcoma; RNA Interference; Tumor Burden; Tumor Cells, Cultured; Young Adult

2011
Inhibition of IGF-1R-dependent PI3K activation sensitizes colon cancer cells specifically to DR5-mediated apoptosis but not to rhTRAIL.
    Cellular oncology (Dordrecht), 2011, Volume: 34, Issue:3

    Topics: Antibodies, Neoplasm; Apoptosis; CASP8 and FADD-Like Apoptosis Regulating Protein; Caspase 8; Cell Line, Tumor; Colonic Neoplasms; Death Domain Receptor Signaling Adaptor Proteins; Enzyme Activation; Humans; Models, Biological; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Pyrimidines; Pyrroles; Receptor, IGF Type 1; Receptors, TNF-Related Apoptosis-Inducing Ligand; Recombinant Proteins; Signal Transduction; TNF-Related Apoptosis-Inducing Ligand

2011
Factors influencing the inhibition of protein kinases.
    Journal of enzyme inhibition and medicinal chemistry, 2012, Volume: 27, Issue:2

    Topics: Adenosine Triphosphate; Drug Discovery; Enzyme Inhibitors; Humans; Kinetics; Magnesium; Peptide Fragments; Protein Conformation; Protein Kinase Inhibitors; Protein Kinases; Pyrimidines; Pyrroles; Receptor, IGF Type 1; Staurosporine; Substrate Specificity

2012
Enhanced efficacy of IGF1R inhibition in pediatric glioblastoma by combinatorial targeting of PDGFRα/β.
    Molecular cancer therapeutics, 2011, Volume: 10, Issue:8

    Topics: Animals; Antineoplastic Agents; Autophagy; Cell Line, Tumor; Child; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Mice; Mice, Nude; Neoplasm Staging; Phosphatidylinositol 3-Kinases; Pyrimidines; Pyrroles; Receptor, IGF Type 1; Receptor, Platelet-Derived Growth Factor alpha; Receptor, Platelet-Derived Growth Factor beta; Signal Transduction; Xenograft Model Antitumor Assays

2011
Insulin-like growth factor-type 1 receptor inhibitor NVP-AEW541 enhances radiosensitivity of PTEN wild-type but not PTEN-deficient human prostate cancer cells.
    International journal of radiation oncology, biology, physics, 2011, Sep-01, Volume: 81, Issue:1

    Topics: Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; DNA Breaks, Double-Stranded; DNA Repair; Down-Regulation; Humans; Male; Neoplasm Proteins; Prostatic Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Pyrimidines; Pyrroles; Radiation Tolerance; Radiation-Sensitizing Agents; Receptor, IGF Type 1

2011
Polo-like kinase 1 inhibition as a new therapeutic modality in therapy of cholangiocarcinoma.
    Anticancer research, 2011, Volume: 31, Issue:10

    Topics: Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cholangiocarcinoma; Deoxycytidine; Fluorouracil; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Polo-Like Kinase 1; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pteridines; Pyrimidines; Pyrroles; RNA, Messenger

2011
K-Ras mutation-mediated IGF-1-induced feedback ERK activation contributes to the rapalog resistance in pancreatic ductal adenocarcinomas.
    Cancer letters, 2012, Sep-01, Volume: 322, Issue:1

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Drug Resistance, Neoplasm; Enzyme Activation; Everolimus; Extracellular Signal-Regulated MAP Kinases; Feedback, Physiological; Female; Humans; Insulin-Like Growth Factor I; MAP Kinase Signaling System; Mechanistic Target of Rapamycin Complex 1; Mice; Multiprotein Complexes; Mutation; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Proteins; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Pyridines; Pyrimidines; Pyrroles; ras Proteins; Sirolimus; Sorafenib; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays

2012
Dependence of Wilms tumor cells on signaling through insulin-like growth factor 1 in an orthotopic xenograft model targetable by specific receptor inhibition.
    Proceedings of the National Academy of Sciences of the United States of America, 2012, May-15, Volume: 109, Issue:20

    Topics: Analysis of Variance; Animals; Cell Line, Tumor; Electrochemistry; Gene Expression Profiling; HEK293 Cells; Humans; Insulin-Like Growth Factor I; Kidney Neoplasms; Magnetic Resonance Imaging; Mice; Paracrine Communication; Phosphorylation; Pyrimidines; Pyrroles; Receptor, IGF Type 1; Signal Transduction; Transplantation, Heterologous; Wilms Tumor

2012
Repression of malignant tumor progression upon pharmacologic IGF1R blockade in a mouse model of insulinoma.
    Molecular cancer research : MCR, 2012, Volume: 10, Issue:6

    Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Survival; Disease Models, Animal; Dose-Response Relationship, Drug; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Immunoblotting; In Situ Nick-End Labeling; Insulinoma; Mice; Mice, Transgenic; Oligonucleotide Array Sequence Analysis; Pancreatic Neoplasms; Phosphorylation; Pyrimidines; Pyrroles; Receptor, IGF Type 1; Reverse Transcriptase Polymerase Chain Reaction; Tumor Burden

2012
Combined blockade of signalling pathways shows marked anti-tumour potential in phaeochromocytoma cell lines.
    Journal of molecular endocrinology, 2012, Volume: 49, Issue:2

    Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Survival; Dose-Response Relationship, Drug; Everolimus; Extracellular Signal-Regulated MAP Kinases; Imidazoles; Lovastatin; Mechanistic Target of Rapamycin Complex 1; Mice; Multiprotein Complexes; PC12 Cells; Protein Kinase Inhibitors; Proteins; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; Quinolines; Receptor, IGF Type 1; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases

2012
Esophageal cancer exhibits resistance to a novel IGF-1R inhibitor NVP-AEW541 with maintained RAS-MAPK activity.
    Anticancer research, 2012, Volume: 32, Issue:7

    Topics: Cell Growth Processes; Cell Line, Tumor; Drug Resistance, Neoplasm; Esophageal Neoplasms; Humans; MAP Kinase Signaling System; Mitogen-Activated Protein Kinases; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; raf Kinases; ras Proteins; Receptor, IGF Type 1

2012
Identification of common and distinctive mechanisms of resistance to different anti-IGF-IR agents in Ewing's sarcoma.
    Molecular endocrinology (Baltimore, Md.), 2012, Volume: 26, Issue:9

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Humans; Immunoglobulins, Intravenous; Insulin-Like Growth Factor II; Pyrimidines; Pyrroles; Receptor, IGF Type 1; Receptor, Insulin; Sarcoma, Ewing; Signal Transduction

2012
Mechanisms of acquired resistance to insulin-like growth factor 1 receptor inhibitor in MCF-7 breast cancer cell line.
    Investigational new drugs, 2013, Volume: 31, Issue:2

    Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Breast Neoplasms; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; Everolimus; Female; Humans; Immunosuppressive Agents; Phosphorylation; Pyrimidines; Pyrroles; Receptor, IGF Type 1; Ribosomal Protein S6 Kinases; Sirolimus; Tumor Cells, Cultured

2013
Evaluation of IGF1R and phosphorylated IGF1R as targets in HER2-positive breast cancer cell lines and tumours.
    Breast cancer research and treatment, 2012, Volume: 136, Issue:3

    Topics: Age Factors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cytoplasm; Female; Humans; Middle Aged; Molecular Targeted Therapy; Phosphorylation; Protein Kinase Inhibitors; Pyridones; Pyrimidines; Pyrroles; Receptor, ErbB-2; Receptor, IGF Type 1; Trastuzumab; Treatment Outcome

2012
Treatment with a combination of the ErbB (HER) family blocker afatinib and the IGF-IR inhibitor, NVP-AEW541 induces synergistic growth inhibition of human pancreatic cancer cells.
    BMC cancer, 2013, Jan-31, Volume: 13

    Topics: Afatinib; Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Drug Therapy, Combination; Humans; Pancreatic Neoplasms; Pyrimidines; Pyrroles; Quinazolines; Receptor, ErbB-3; Receptor, IGF Type 1

2013
Potentiating the efficacy of molecular targeted therapy for hepatocellular carcinoma by inhibiting the insulin-like growth factor pathway.
    PloS one, 2013, Volume: 8, Issue:6

    Topics: Animals; Antineoplastic Agents; Blotting, Western; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Cells, Cultured; Checkpoint Kinase 2; Drug Resistance, Neoplasm; Drug Synergism; Humans; Indoles; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Receptor, IGF Type 1; RNA Interference; Signal Transduction; Sorafenib; Sunitinib; Xenograft Model Antitumor Assays

2013
Vertical blockade of the IGFR- PI3K/Akt/mTOR pathway for the treatment of hepatocellular carcinoma: the role of survivin.
    Molecular cancer, 2014, Jan-03, Volume: 13

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Blotting, Western; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Drug Synergism; Enzyme Inhibitors; Everolimus; Flow Cytometry; Heterocyclic Compounds, 3-Ring; Humans; Imidazoles; Inhibitor of Apoptosis Proteins; Liver Neoplasms; Male; Mice, Inbred BALB C; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; Quinolines; Receptors, Somatomedin; Signal Transduction; Sirolimus; Survivin; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays

2014
IGF1 induces cell proliferation in human pituitary tumors - functional blockade of IGF1 receptor as a novel therapeutic approach in non-functioning tumors.
    Molecular and cellular endocrinology, 2014, Jun-05, Volume: 390, Issue:1-2

    Topics: Adenoma; Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Cyclin D3; Female; Humans; Insulin-Like Growth Factor I; Male; Middle Aged; Pituitary Neoplasms; Protein Processing, Post-Translational; Pyrimidines; Pyrroles; Rats

2014
Co-targeting the IGF system and HIF-1 inhibits migration and invasion by (triple-negative) breast cancer cells.
    British journal of cancer, 2014, Jun-10, Volume: 110, Issue:12

    Topics: Antibodies, Monoclonal; Cell Hypoxia; Cell Line, Tumor; Cell Movement; Female; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Insulin-Like Growth Factor I; Insulin-Like Growth Factor II; MCF-7 Cells; Pyrimidines; Pyrroles; Receptor, IGF Type 1; Signal Transduction; Topoisomerase I Inhibitors; Topotecan; Triple Negative Breast Neoplasms

2014
Cotargeting of epidermal growth factor receptor and PI3K overcomes PI3K-Akt oncogenic dependence in pancreatic ductal adenocarcinoma.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2014, Aug-01, Volume: 20, Issue:15

    Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Pancreatic Ductal; Cell Cycle; Cell Movement; Cell Proliferation; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Fluorescent Antibody Technique; Humans; Immunoenzyme Techniques; Mice; Mice, Inbred NOD; Mice, SCID; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; Quinazolines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Thiazoles; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2014
IGF1R tyrosine kinase inhibitor enhances the cytotoxic effect of methyl jasmonate in endometrial cancer.
    Cancer letters, 2014, Oct-01, Volume: 352, Issue:2

    Topics: Acetates; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cyclopentanes; Dose-Response Relationship, Drug; Endometrial Neoplasms; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Oxylipins; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; Receptor, IGF Type 1; Time Factors

2014
Upregulation of IGF1R by mutant RAS in leukemia and potentiation of RAS signaling inhibitors by small-molecule inhibition of IGF1R.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2014, Nov-01, Volume: 20, Issue:21

    Topics: Animals; Apoptosis; Benzimidazoles; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Female; Genes, ras; Humans; Leukemia, Myeloid, Acute; Mice; Mitogen-Activated Protein Kinase Kinases; Pyrimidines; Pyrroles; Receptor, IGF Type 1; Signal Transduction; Small Molecule Libraries; Up-Regulation

2014
EGFR and IGF-1R in regulation of prostate cancer cell phenotype and polarity: opposing functions and modulation by T-cadherin.
    FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2015, Volume: 29, Issue:2

    Topics: Cadherins; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cell Survival; Collagen; Drug Combinations; ErbB Receptors; Gefitinib; Gene Silencing; Golgi Apparatus; Humans; Laminin; Male; Neoplasm Invasiveness; Phenotype; Phosphorylation; Prostate; Prostatic Neoplasms; Proteoglycans; Pyrimidines; Pyrroles; Quinazolines; Receptor, IGF Type 1

2015
HDAC inhibitors increase NRF2-signaling in tumour cells and blunt the efficacy of co-adminstered cytotoxic agents.
    PloS one, 2014, Volume: 9, Issue:11

    Topics: Acrolein; Antineoplastic Agents; Antioxidant Response Elements; Cell Line, Tumor; Cytotoxins; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Humans; Neoplasms; NF-E2-Related Factor 2; Proto-Oncogene Proteins c-pim-1; Pyrimidines; Pyrroles; Receptor, IGF Type 1; Signal Transduction

2014
Insulin-like growth factors inhibit dendritic cell-mediated anti-tumor immunity through regulating ERK1/2 phosphorylation and p38 dephosphorylation.
    Cancer letters, 2015, Apr-01, Volume: 359, Issue:1

    Topics: Animals; Antineoplastic Agents; Ascites; Cell Line, Tumor; Coculture Techniques; Dendritic Cells; Female; Humans; Immunity, Cellular; Insulin-Like Growth Factor I; Insulin-Like Growth Factor II; Interferon-gamma; Interleukins; Lymphocyte Activation; Mice, Inbred C57BL; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Neoplasm Staging; Ovarian Neoplasms; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Pyrimidines; Pyrroles; Receptor, IGF Type 1; Signal Transduction; T-Lymphocytes, Cytotoxic; Time Factors; Transfection; Tumor Necrosis Factor-alpha

2015
Picropodophyllin inhibits proliferation and survival of diffuse large B-cell lymphoma cells.
    Medical oncology (Northwood, London, England), 2015, Volume: 32, Issue:7

    Topics: Apoptosis; Cell Line; Cell Line, Tumor; Cell Proliferation; Cell Survival; Humans; Insulin-Like Growth Factor I; Insulin-Like Growth Factor II; Lymphoma, Large B-Cell, Diffuse; MAP Kinase Signaling System; Phosphorylation; Podophyllotoxin; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; Receptor, IGF Type 1; Signal Transduction

2015
Evaluation of In Vitro Activity of the Class I PI3K Inhibitor Buparlisib (BKM120) in Pediatric Bone and Soft Tissue Sarcomas.
    PloS one, 2015, Volume: 10, Issue:9

    Topics: Aminopyridines; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Class I Phosphatidylinositol 3-Kinases; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Humans; Mechanistic Target of Rapamycin Complex 1; Morpholines; Multiprotein Complexes; Mutation; Osteosarcoma; Phosphorylation; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Pyridones; Pyrimidines; Pyrimidinones; Pyrroles; Sarcoma; Signal Transduction; TOR Serine-Threonine Kinases

2015
Identification of a 5-[3-phenyl-(2-cyclic-ether)-methylether]-4-aminopyrrolo[2,3-d]pyrimidine series of IGF-1R inhibitors.
    Bioorganic & medicinal chemistry letters, 2016, Apr-15, Volume: 26, Issue:8

    Topics: Crystallography, X-Ray; Dose-Response Relationship, Drug; Humans; Microsomes, Liver; Models, Molecular; Molecular Structure; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Receptor, IGF Type 1; Structure-Activity Relationship

2016
Optimisation of a 5-[3-phenyl-(2-cyclic-ether)-methyl-ether]-4-aminopyrrolopyrimidine series of IGF-1R inhibitors.
    Bioorganic & medicinal chemistry letters, 2016, Apr-15, Volume: 26, Issue:8

    Topics: Animals; Antineoplastic Agents; Cell Proliferation; Dose-Response Relationship, Drug; Humans; Imidazoles; Mice; Mice, Nude; Molecular Structure; Neoplasms, Experimental; NIH 3T3 Cells; Protein Kinase Inhibitors; Pyrazines; Pyrimidines; Pyrroles; Receptor, IGF Type 1; Structure-Activity Relationship; Xenograft Model Antitumor Assays

2016
Co-inhibition of EGFR and IGF1R synergistically impacts therapeutically on adrenocortical carcinoma.
    Oncotarget, 2016, Jun-14, Volume: 7, Issue:24

    Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Survival; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Male; Mice, Nude; Middle Aged; Pyrimidines; Pyrroles; Receptor, IGF Type 1; Xenograft Model Antitumor Assays

2016
Intestinal adaptation in proximal and distal segments: Two epithelial responses diverge after intestinal separation.
    Surgery, 2017, Volume: 161, Issue:4

    Topics: Adaptation, Physiological; Animals; beta Catenin; Biomarkers; Biopsy, Needle; Cell Proliferation; Disease Models, Animal; Immunohistochemistry; Intestinal Mucosa; Intestine, Small; Male; Pyrimidines; Pyrroles; Random Allocation; Real-Time Polymerase Chain Reaction; Reference Values; Sensitivity and Specificity; Short Bowel Syndrome; Zebrafish

2017
Co-Targeting IGF-1R and Autophagy Enhances the Effects of Cell Growth Suppression and Apoptosis Induced by the IGF-1R Inhibitor NVP-AEW541 in Triple-Negative Breast Cancer Cells.
    PloS one, 2017, Volume: 12, Issue:1

    Topics: Adenine; Apoptosis; Autophagy; Autophagy-Related Protein 7; Cell Line, Tumor; Cell Proliferation; Female; G1 Phase Cell Cycle Checkpoints; Humans; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; Receptor, IGF Type 1; RNA, Small Interfering; Signal Transduction; Triple Negative Breast Neoplasms

2017
HASF (C3orf58) is a novel ligand of the insulin-like growth factor 1 receptor.
    The Biochemical journal, 2017, 02-20, Volume: 474, Issue:5

    Topics: Adaptor Proteins, Vesicular Transport; Animals; Animals, Newborn; Binding Sites; Cell Proliferation; Gene Expression Regulation; Heart Ventricles; HEK293 Cells; Humans; Ligands; Membrane Proteins; Mice; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Myocytes, Cardiac; Phosphorylation; Primary Cell Culture; Protein Binding; Pyrimidines; Pyrroles; Rats; Rats, Sprague-Dawley; Receptor, IGF Type 1; Receptor, IGF Type 2; Receptor, Insulin; RNA, Small Interfering; Signal Transduction; Two-Hybrid System Techniques

2017
Inhibition of the insulin-like growth factor-1 receptor potentiates acute effects of castration in a rat model for prostate cancer growth in bone.
    Clinical & experimental metastasis, 2017, Volume: 34, Issue:3-4

    Topics: Animals; Apoptosis; Bone Neoplasms; Cell Proliferation; Disease Models, Animal; Humans; Male; Neoplasm Staging; Phosphorylation; Prognosis; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Pyrimidines; Pyrroles; Rats; Receptor, IGF Type 1; Receptors, Somatomedin; Signal Transduction; Survival Rate; Tumor Cells, Cultured

2017
Dual inhibition of IGF1R and ER enhances response to trastuzumab in HER2 positive breast cancer cells.
    International journal of oncology, 2017, Volume: 50, Issue:6

    Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Disease-Free Survival; Estrogen Receptor alpha; Female; Gene Expression Regulation, Neoplastic; Humans; Pyrimidines; Pyrroles; Receptor, ErbB-2; Receptor, IGF Type 1; Receptors, Somatomedin; Tamoxifen; Trastuzumab; Xenograft Model Antitumor Assays

2017
Synergistic effects of various Her inhibitors in combination with IGF-1R, C-MET and Src targeting agents in breast cancer cell lines.
    Scientific reports, 2017, 06-21, Volume: 7, Issue:1

    Topics: Afatinib; Antineoplastic Agents; Breast Neoplasms; Cell Cycle; Cell Enlargement; Cell Line, Tumor; Cell Movement; Crizotinib; Dasatinib; Female; Humans; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrimidines; Pyrroles; Quinolines; Receptor, ErbB-2; Receptor, IGF Type 1; src-Family Kinases

2017
Kinase inhibitors of the IGF-1R as a potential therapeutic agent for rheumatoid arthritis.
    Autoimmunity, 2017, Volume: 50, Issue:5

    Topics: Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Cell Line; Cell Proliferation; Female; Humans; Insulin-Like Growth Factor I; Macrophage Colony-Stimulating Factor; Mice; Neovascularization, Pathologic; Osteoclasts; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; RANK Ligand; Receptor, IGF Type 1; Receptors, Somatomedin; Signal Transduction

2017
Receptors for Insulin-Like Growth Factor-2 and Androgens as Therapeutic Targets in Triple-Negative Breast Cancer.
    International journal of molecular sciences, 2017, Nov-02, Volume: 18, Issue:11

    Topics: Androgen Antagonists; Androgens; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cell Line, Tumor; Cell Proliferation; Cell Survival; Female; Humans; Insulin-Like Growth Factor II; Molecular Targeted Therapy; Nitriles; Phenylthiohydantoin; Pyrazoles; Pyrimidines; Pyrroles; Receptor, IGF Type 1; Signal Transduction; Triazines; Triple Negative Breast Neoplasms

2017
Co-targeting PI3K, mTOR, and IGF1R with small molecule inhibitors for treating undifferentiated pleomorphic sarcoma.
    Cancer biology & therapy, 2017, 10-03, Volume: 18, Issue:10

    Topics: Animals; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p27; Enzyme Inhibitors; Female; Humans; Imidazoles; Mice; Mice, Hairless; Mice, SCID; Molecular Targeted Therapy; Phosphatidylinositol 3-Kinase; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; Quinolines; Receptor, IGF Type 1; Receptors, Somatomedin; Sarcoma; Signal Transduction; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays

2017
Inhibition of PI3K/Akt/mTOR overcomes cisplatin resistance in the triple negative breast cancer cell line HCC38.
    BMC cancer, 2017, Nov-03, Volume: 17, Issue:1

    Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Drug Resistance, Neoplasm; Drug Synergism; Humans; Imidazoles; Lapatinib; Phosphatidylinositol 3-Kinases; Phosphorylation; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; Quinazolines; Quinolines; Signal Transduction; TOR Serine-Threonine Kinases; Triple Negative Breast Neoplasms

2017
Nuclear IGF-1R predicts chemotherapy and targeted therapy resistance in metastatic colorectal cancer.
    British journal of cancer, 2017, Dec-05, Volume: 117, Issue:12

    Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cell Nucleus; Cell Survival; Cetuximab; Colorectal Neoplasms; Curcumin; Dasatinib; Drug Resistance, Neoplasm; Fatty Acids, Unsaturated; Female; Fluorouracil; Gene Silencing; HCT116 Cells; HT29 Cells; Humans; Leucovorin; Male; Middle Aged; Molecular Chaperones; Molecular Targeted Therapy; Niacinamide; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Phenylurea Compounds; Protein Inhibitors of Activated STAT; Protein Transport; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Pyrimidines; Pyrroles; Receptor, IGF Type 1; Signal Transduction; Sorafenib

2017
Insulin-like growth factor 1 receptor signaling regulates embryonic epicardial cell proliferation through focal adhesion kinase pathway.
    Acta biochimica et biophysica Sinica, 2018, Oct-01, Volume: 50, Issue:10

    Topics: Animals; Cell Proliferation; Cells, Cultured; Focal Adhesion Kinase 1; Insulin-Like Growth Factor I; Insulin-Like Growth Factor II; Mice, Inbred C57BL; Pericardium; Podophyllotoxin; Pyrimidines; Pyrroles; Receptor, IGF Type 1; Signal Transduction

2018
IGF-1 alleviates serum IgG-induced neuronal cytolysis through PI3K signaling in children with opsoclonus-myoclonus syndrome and neuroblastoma.
    Pediatric research, 2019, Volume: 85, Issue:6

    Topics: Animals; Cells, Cultured; Child, Preschool; Chromones; Female; Humans; Immunoglobulin G; Insulin-Like Growth Factor I; Male; Morpholines; Neuroblastoma; Neurons; Opsoclonus-Myoclonus Syndrome; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Pyrimidines; Pyrroles; Rats; Receptor, IGF Type 1; Signal Transduction

2019
Two old drugs, NVP-AEW541 and GSK-J4, repurposed against the Toxoplasma gondii RH strain.
    Parasites & vectors, 2020, May-11, Volume: 13, Issue:1

    Topics: Animals; Antiprotozoal Agents; Benzazepines; Cell Survival; Drug Repositioning; Female; Fibroblasts; Foreskin; Humans; Male; Mice; Mice, Inbred BALB C; Parasite Load; Pyrimidines; Pyrroles; Toxoplasma; Toxoplasmosis

2020
Maresin-1 induces cardiomyocyte hypertrophy through IGF-1 paracrine pathway.
    American journal of physiology. Cell physiology, 2021, 07-01, Volume: 321, Issue:1

    Topics: Animals; Cardiomegaly; Cardiotonic Agents; Disease Models, Animal; Docosahexaenoic Acids; Gene Expression Regulation; Insulin-Like Growth Factor I; Male; Mice; Mice, Inbred C57BL; Myocardial Infarction; Myocytes, Cardiac; Nuclear Receptor Subfamily 1, Group F, Member 1; Paracrine Communication; Phosphatidylinositol 3-Kinases; Primary Cell Culture; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; Rats; Ribonucleosides; Signal Transduction; Sulfonamides; Thiophenes; Wortmannin

2021